Ipsen’s activities require optimum security levels and a strategy which is respectful of the environment. Ipsen’s commitment is formalized by way of a comprehensive environment, health and safety (ehs) policy, based on the ISO 14001 (environment) and OHSAS 18001 (health and safety) guidelines.
A five-year EHS plan was rolled out in 2008 to control risks to employee health and safety in the workplace and to reduce the Group's environmental footprint. All production sites at which the EHS management system is deployed have reached a satisfactory level of compliance with internal requirements. Since 2010, internal audits are conducted at all Ipsen sites to assess compliance with applicable requirements and the Group's standards. The EHS department plans to extend this program to sub-contracting sites in the near future.
Two new sites, Dreux and Signes (France), obtained ISO 14001 certification in 2011, demonstrating their commitment to environmental issues. L’Isle-sur-la-Sorgue (France), Cork (Ireland) and Tianjin (China) sites obtained their certification in 2004, 2008 and 2010, respectively. Certification is renewed each year and is part of Ipsen's continuous improvement policy. Dreux (France) also obtained OHSAS 18001 certification in 2012. This certificate was granted to Ipsen’s Cork (Ireland) facility in 2010.
The Wrexham facility in the UK obtained BS 8555 certification and was also awarded the Corporate Health Standard in recognition of its efforts to promote health and safety in the workplace, and the RoSpa gold award (Royal Society for the prevention of accidents) for safety.
Ipsen renewed and extended its environment, health and safety awareness and training program in 2011. Each site rolled out its program according to its specific risks and impacts. All employees received training in the risks inherent to their roles and the environmental impacts associated with their activities. This preventive approach helps employees adopt a responsible attitude in their day-to-day work.
The Group is voluntarily pursuing a policy to assess and reduce greenhouse gas emissions in order to counteract the effects of global warming. In France, in 2009, the Group teamed up with the French association of pharmaceutical companies (Leem) to initiate a process to quantify the sector’s greenhouse gas emissions using a common and consistent methodology. The Signes and Dreux (France) facilities have since begun a pilot process to assess their CO2 emissions.
At end 2011, the research center at Les Ulis (France) and the sites at L’Isle-sur-la-Sorgue (France), Cork (Ireland), Signes (France) and Wrexham (UK) produced detailed reports on their greenhouse gas emissions.
The carbon reporting system will be strengthened in 2012, together with A plan to reduce the Group's carbon footprint and place its “Energy plan” at the heart of Ipsen's initiatives.
A plan to reduce the Group's carbon footprint will be strengthened in 2012, together with a plan to place its “Energy plan” at the heart of Ipsen's initiatives.